Sysmex (OTCMKTS:SSMXY) Sets New 12-Month Low After Earnings Miss

Sysmex Corporation ADR (OTCMKTS:SSMXY)’s share price reached a new 52-week low during trading on Thursday after the company announced weaker than expected quarterly earnings. The stock traded as low as $8.12 and last traded at $8.12, with a volume of 553102 shares traded. The stock had previously closed at $8.46.

The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). Sysmex had a net margin of 8.86% and a return on equity of 9.27%. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS.

Analysts Set New Price Targets

Separately, Citigroup cut Sysmex from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 16th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Sysmex Price Performance

The firm has a market capitalization of $5.11 billion, a PE ratio of 16.92 and a beta of 1.10. The stock has a 50-day moving average price of $8.75 and a 200 day moving average price of $9.42. The company has a quick ratio of 2.44, a current ratio of 3.33 and a debt-to-equity ratio of 0.12.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.